TY - JOUR
T1 - Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence
T2 - An Analysis of the EUGEI Study
AU - Rodríguez-Toscano, Elisa
AU - Alloza, Clara
AU - Fraguas, David
AU - Durán-Cutilla, Manuel
AU - Roldán, Laura
AU - Sánchez-Gutiérrez, Teresa
AU - López-Montoya, Gonzalo
AU - Parellada, Mara
AU - Moreno, Carmen
AU - Gayer-Anderson, Charlotte
AU - Jongsma, Hannah E.
AU - di Forti, Marta
AU - Quattrone, Diego
AU - Velthorst, Eva
AU - de Haan, Lieuwe
AU - Selten, Jean-Paul
AU - Szöke, Andrei
AU - Llorca, Pierre-Michel
AU - Tortelli, Andrea
AU - Bobes, Julio
AU - Bernardo, Miguel
AU - Sanjuán, Julio
AU - Luis Santos, José
AU - Arrojo, Manuel
AU - Tarricone, Ilaria
AU - Berardi, Domenico
AU - Ruggeri, Mirella
AU - Lasalvia, Antonio
AU - Ferraro, Laura
AU - la Cascia, Caterina
AU - la Barbera, Daniele
AU - Menezes, Paulo Rossi
AU - del-Ben, Cristina Marta
AU - EU-GEI WP2 Group
AU - Amoretti, Silvia
AU - Andreu-Bernabeu, Alvaro
AU - Baudin, Grégoire
AU - Beards, Stephanie
AU - Bonora, Elena
AU - Bonetto, Chiara
AU - Cabrera, Bibiana
AU - Carracedo, Angel
AU - Charpeaud, Thomas
AU - Costas, Javier
AU - Cristofalo, Doriana
AU - Cuadrado, Pedro
AU - D'Andrea, Giuseppe
AU - Ferchiou, Aziz
AU - Franke, Nathalie
AU - Termorshuizen, Fabian
AU - van Dam, Daniella
N1 - Funding Information: Supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE, PI14/00397, PI17/00481, PI20/00216, PI20/00721, JR19/00024), CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB/07/09/0023); Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Structural Funds, European Union Seventh Framework Programme, European Union H2020 Programme under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No.101034377 (Project PRISM-2), and grant agreement No 777394 (Project AIMS-2-TRIALS)), European Union Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme. The Brazilian study was funded by grant 2012/0417-0 from the São Paulo Research Foundation. The study sponsors did not play any role in the study design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Funding Information: Dr. Fraguas has been a consultant and/or has received fees from Angelini, Casen-Recardati, Janssen, Lundbeck, and Otsuka. He has also received grant support from Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation) and from Fundación Alicia Koplowitz. Dr. Díaz-Caneja has received honoraria from Exeltis and Angelini. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Dr. Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi, and Takeda. Dr. Murray has received honoraria from Janssen, Sunovian, Otsuka, and Lundbeck. Dr. Moreno has received honoraria as a consultant and/or advisor and/or for lectures from Angelini, Esteve, Exeltis Janssen, Lundbeck, Neuraxpharm, Nuvelution, Otsuka, Pfizer, Servier, and Sunovion outside the submitted work. The other authors have no conflicts of interest to declare. Dr. Jones has received an honorarium from MSD. Publisher Copyright: © 2023 The Author(s). Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Background: Use of illegal stimulants is associated with an increased risk of psychotic disorder. However, the impact of stimulant use on odds of first-episode psychosis (FEP) remains unclear. Here, we aimed to describe the patterns of stimulant use and examine their impact on odds of FEP. Methods: We included patients with FEP aged 18-64 years who attended psychiatric services at 17 sites across 5 European countries and Brazil, and recruited controls representative of each local population (FEP = 1130; controls = 1497). Patterns of stimulant use were described. We computed fully adjusted logistic regression models (controlling for age, sex, ethnicity, cannabis use, and education level) to estimate their association with odds of FEP. Assuming causality, we calculated the population-attributable fractions for stimulant use associated with the odds for FEP. Findings: Prevalence of lifetime and recent stimulant use in the FEP sample were 14.50% and 7.88% and in controls 10.80% and 3.8%, respectively. Recent and lifetime stimulant use was associated with increased odds of FEP compared with abstainers [fully adjusted odds ratio 1.74,95% confidence interval (CI) 1.20-2.54, P =. 004 and 1.62, 95% CI 1.25-2.09, P <. 001, respectively]. According to PAFs, a substantial number of FEP cases (3.35% [95% CI 1.31-4.78] for recent use and 7.61% [95% CI 3.68-10.54] for lifetime use) could have been prevented if stimulants were no longer available and the odds of FEP and PAFs for lifetime and recent stimulant use varied across countries. Interpretation: Illegal stimulant use has a significant and clinically relevant influence on FEP incidence, with varying impacts across countries.
AB - Background: Use of illegal stimulants is associated with an increased risk of psychotic disorder. However, the impact of stimulant use on odds of first-episode psychosis (FEP) remains unclear. Here, we aimed to describe the patterns of stimulant use and examine their impact on odds of FEP. Methods: We included patients with FEP aged 18-64 years who attended psychiatric services at 17 sites across 5 European countries and Brazil, and recruited controls representative of each local population (FEP = 1130; controls = 1497). Patterns of stimulant use were described. We computed fully adjusted logistic regression models (controlling for age, sex, ethnicity, cannabis use, and education level) to estimate their association with odds of FEP. Assuming causality, we calculated the population-attributable fractions for stimulant use associated with the odds for FEP. Findings: Prevalence of lifetime and recent stimulant use in the FEP sample were 14.50% and 7.88% and in controls 10.80% and 3.8%, respectively. Recent and lifetime stimulant use was associated with increased odds of FEP compared with abstainers [fully adjusted odds ratio 1.74,95% confidence interval (CI) 1.20-2.54, P =. 004 and 1.62, 95% CI 1.25-2.09, P <. 001, respectively]. According to PAFs, a substantial number of FEP cases (3.35% [95% CI 1.31-4.78] for recent use and 7.61% [95% CI 3.68-10.54] for lifetime use) could have been prevented if stimulants were no longer available and the odds of FEP and PAFs for lifetime and recent stimulant use varied across countries. Interpretation: Illegal stimulant use has a significant and clinically relevant influence on FEP incidence, with varying impacts across countries.
KW - amphetamines
KW - first episode psychosis
KW - methamphetamine
KW - population attributable fractions
KW - stimulant use
UR - http://www.scopus.com/inward/record.url?scp=85172471950&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/schbul/sbad013
DO - https://doi.org/10.1093/schbul/sbad013
M3 - Article
C2 - 37467351
SN - 0586-7614
VL - 49
SP - 1269
EP - 1280
JO - Schizophrenia Bulletin
JF - Schizophrenia Bulletin
IS - 5
ER -